HOSPITAL PROFILE

HOSPITAL PROFILE

The Eastern Hepatobiliary Surgery Hospital(EHBH)，including the Eastern Institute for Hepatobiliary Surgery Research，is the 3rdaffiliated hospital of the Second Military Medical University of the Chinese People’s Liberation Army(CPLA).Through self-reliance，hard working，unyielding efforts and dashing spirit for more than 50 years under the leadership of Professor WU Mengchao，a world-famous expert in hepatobiliary surgery，one of the main pioneers and originators of hepatobiliary surgery in China，and a member of the Chinese Academy of Sciences，EHBH has grown from a three-person group in 1956 to the only hepatobiliary surgery specialist hospital with a built-in research institute in China that merges medical care services，training and scientific research into an integral framework.It has become a national key discipline，a state-level base for continuing medical education，a CPLA hepatobiliary surgery center，a CPLA institute for hepatobiliary surgery research，a key laboratory of the Ministry of Education and CPLA，and a CPLA “primary key discipline”，a leading key discipline in medical science in Shanghai.Approved as a“Class III Grade A”specialist hospital by the CPLA General Logistics Department.Now the hospital has 742 beds and is equipped with the latest instruments and equipment with a total value of RMB two hundred million yuan.EHBH has reached the international level and the leading domestic level in the early detection and early treatment of primary liver cancer，comprehensive treatment of middle-advanced stage liver cancer，postoperative anti-recurrence therapy of primary liver cancer，immunotherapeutic interventions against tumors，surgical treatment of complex hepatobiliary diseases，endoscopic treatment of hepatobiliary diseases，and liver transplantation.

Now the yearly outpatient capacity is about 160 000 persons/times，and the yearly number of hospitalized patients is more than 24 000 persons/times.By December 2011，Dr.WU Mengchao and his colleagues had successfully performed more than 70 000 operations and set up the largest case-bank and specimen-bank of liver cancer in the world.The success rate of liver tumor resection is as high as 99%;the postoperative 5-year overall survival rate is 53.2%;the postoperative 5-year survival rate for small liver cancer is over 80%;and the longest postoperative survival is over 44 years.The hospital tops the world in the number of liver cancer resections，the resection rate and the survival rate.

The hospital has an army of experienced technical personnel with tip-top young talents as the mainstay under the leadership of Academician WU Mengchao，including 71 persons with senior professional titles，a member of the Chinese Academy of Sciences and a member of the Chinese Academy of Engineering.In January 1996，the Chinese Central Military Commission granted WU Mengchao the honorary title“Model Medical Experts”.Other honorary titles and awards won by the staff members of the hospital and the institute include:Distinguished Professor of Cheung Kong Scholars Program(1 person);and so on.

Since 1978，the hospital has trained 20 post-doctoral graduates，143 PhD graduates and 254 master’s degree graduates.In addition，it also undertakes teaching tasks of training overseas students and graduating students majoring in clinical medicine.For many years，the hospital has trained more than one thousand trainees from all parts of the country，and has become a national teaching base for cultivating senior personnel in hepatobiliary surgery.The hospital has won various science and technology prizes and awards，including State Supreme Science and Technology Award(1 project);National Science and Technology Assembly Award(1 project);and so on.

The Eastern Institute for Hepatobiliary Surgery Research headed by Professor WU Mengchao is a CPLA scientific research，medical care service and training center.It is among the first batch of disciplines authorized to confer Master’s Degree in 1979 and Doctoral Degree in 1981 after China resumed the national postgraduate enrollment.In 1991，it was approved as the CPLA open laboratory and the postdoctoral mobile research station of clinical medicine.The institute comprises an institute for anti-tumor immunogene therapy，a biological signal transduction research center，a molecular oncology research room and a virus-based gene therapy laboratory.

Faced with the growing community health needs and the rapid advances in medical science，the hospital spares no effort to seize the opportunity by investing RMB 1.6 billion yuan to build a new hospital in Anting of Shanghai Jiading District.Equipped with 1 500 beds(1 000 beds for the stage-one project)，the new hospital will be a Class III Grade A tertiary general hospital with a complete lists of affiliated units and departments characteristic of distinctive specialty traits.

Co-funded by more than RMB 4 hundred million yuan from the State Development and Reform Commission and Shanghai Government，the State Liver Cancer Center will be settled in Anting，covering an area of 40 acres adjacent to the new hospital.It will serve as a public service platform for liver cancer science，and a national academic exchange and cooperation center.

医院简介

第二军医大学东方肝胆外科医院是著名肝胆外科专家、我国肝胆外科主要奠基人和开拓者、中国科学院院士吴孟超教授创建并领导的院所合一、国内唯一的肝胆外科专科医院，现为国家重点学科，国家级继续医学教育基地，全军肝胆外科专科中心，全军肝胆外科研究所，国家教育部和全军重点实验室，军队“重中之重”建设学科，上海市医学领先专业重点学科，上海市重中之重临床医学中心。开放床位712张，拥有各类先进仪器设备价值1.58亿元。

医院长期坚持医、教、研结合，在原发性肝癌的早期诊断和治疗，中晚期肝癌的综合治疗，原发性肝癌术后抗复发治疗，肿瘤的免疫治疗、介入治疗，复杂胆道疾病的手术治疗，肝胆疾病的内窥镜治疗，以及肝移植等方面均居国内外先进水平。

医院现年门诊量19万多人次，年收治住院病人2.6万余人次。至2012年11月止，已成功实施手术7.5万余例，积累了国际上最大数量的肝癌病例库和标本库，肝癌切除手术成功率达到99%，术后5年总生存率达53.2%，小肝癌术后5年生存率达80%以上，术后生存时间最长的已达44年。肝癌切除例数、切除率、生存率等指标均处于国际领先水平。

医院拥有一支由吴孟超院士领衔，以拔尖中青年为骨干的优秀科技干部队伍，现有高级职称95名，中国科学院院士1名，中国工程院院士1名，博士生导师26名，硕士生导师51名。共培养博士后22名，博士研究生151名，硕士研究生261名，为全国各地培养进修生千余名。获国家最高科学技术奖1项，全国科技大会奖1项，国家科技进步一、二、三等奖5项，国家自然科学二等奖1项，获省部级科技进步和医疗成果奖92项。“十一五”以来获各类课题资助278项，资助经费近3.45亿元。2012年获国家首次设立的科技进步创新团队奖。

医院创始人吴孟超院士1996年1月被中央军委授予“模范医学专家”荣誉称号，2006年1月获国家最高科学技术奖，2012年被评为“感动中国”人物。近年来，医院先后被评为总后勤部“先进党委“、“先进师旅团级单位”、“贯彻科学发展先进单位”和“全军医院管理先进单位”。2008年医院抗震救灾医疗队荣立二等功。

东方肝胆外科研究所作为军队科研、医学和教学的中心，1979年、1981年分别被批准为国家恢复研究生制度后的第一批硕士、博士授权学科。下设肿瘤免疫与基因治疗研究所、生物信号转导研究中心、分子肿瘤研究室、病毒与基因治疗实验室，在肝胆外科及肝癌的基础和临床研究方面始终起着引领作用。

安亭新院规划床位1 500张，一期工程(1 000张)在2013年投入使用，总建筑面积22.28万平方米。

国家肝癌科学中心项目建设全面推进，中心将建设成为国家肝癌集成研究中心、国家肝癌研究优势资源产业平台、高层次肝癌研究人才培养基地、国家肝癌科学的公共服务平台和国家学术交流与合作中心。